| SOFOSBUVIR; VELPATASVIR | None | ||
| 400MG;100MG, 200MG;50MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| EPCLUSA is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection: • without cirrhosis or with compensated cirrhosis • with decompensated cirrhosis for use in combination with ribavirin. | |||
|
Yes
| |||
| EPCLUSA | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||||||||||||||||||||||
| ********** *************** ******** | ********** *************** ******** | ********** *************** ******** | ********** *************** ******** | ********* ********* | ********* ********* | ********** *************** ******** | ********** *************** ******** | ********** **************** | ********** **************** | ********** **************** | ********** **************** | ********** *************** ******** | ********** *************** ******** | ************ *** ******* *** ******** ********* * ***** | ************ *** ******* *** ******** ********* * ***** | ********* ********* | ********* ********* | ********* ********* | ********* ********* | ********** *************** ******** | ********** *************** ******** | ********** **************** | ********** **************** | *********** *********** ** *** ********* ********* | *********** *********** ** *** ********* ********* | *********** *********** ** *** ********* ********* | *********** *********** ** *** ********* ********* | *********** *********** ** *** ********* ********* | *********** *********** ** *** ********* ********* |
| SOFOSBUVIR; VELPATASVIR | None | ||
| 150MG;37.5MG, 200MG;50MG |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| EPCLUSA is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection: • without cirrhosis or with compensated cirrhosis • with decompensated cirrhosis for use in combination with ribavirin. | |||
|
Yes
| |||
| EPCLUSA | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | ||||||||||||||||||||||||||||
| ********** *************** ******** | ********** *************** ******** | ********** *************** ******** | ********** *************** ******** | ********* ********* | ********* ********* | ********** *************** ******** | ********** *************** ******** | ********** **************** | ********** **************** | ********** **************** | ********** **************** | ********** *************** ******** | ********** *************** ******** | ************ *** ******* *** ******** ********* * ***** | ************ *** ******* *** ******** ********* * ***** | ********* ********* | ********* ********* | ********* ********* | ********* ********* | ********** *************** ******** | ********** *************** ******** | ********** **************** | ********** **************** | *********** *********** ** *** ********* ********* | *********** *********** ** *** ********* ********* | *********** *********** ** *** ********* ********* | *********** *********** ** *** ********* ********* |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|